The perfect pathology report after neoadjuvant therapy

Journal of the National Cancer Institute - Monographs

Volumn 2015, Issue 51, 2015, Pages 47-50

  Marchiò, Caterina ^a   Maletta, Francesca ^a   Annaratone, Laura ^a   Sapino, Anna ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ARTICLE; AXILLARY LYMPH NODE; BREAST BIOPSY; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CARCINOMA IN SITU; CLINICAL EVALUATION; DIAGNOSTIC IMAGING; DIAGNOSTIC TEST ACCURACY STUDY; HISTOPATHOLOGY; HUMAN; IMMUNOCYTOCHEMISTRY; INTRADUCTAL CARCINOMA; INVASIVE CARCINOMA; MICROSCOPY; MINIMAL RESIDUAL DISEASE; PARAMETERS; PATHOLOGIST; PATHOPHYSIOLOGY; PREDICTIVE VALUE; PRIORITY JOURNAL; SENTINEL LYMPH NODE BIOPSY; TISSUE SECTION; TREATMENT RESPONSE; BIOPSY; BREAST; BREAST NEOPLASMS; COOPERATION; FEMALE; NEOADJUVANT THERAPY; NEOPLASM, RESIDUAL; ONCOLOGY; OUTCOME ASSESSMENT; PATHOLOGY; PROCEDURES; PROFESSIONAL COMPETENCE; PROGNOSIS; SPECIMEN HANDLING; STANDARDS;

BIOPSY; BREAST; BREAST NEOPLASMS; COOPERATIVE BEHAVIOR; FEMALE; HUMANS; MEDICAL ONCOLOGY; NEOADJUVANT THERAPY; NEOPLASM, RESIDUAL; OUTCOME ASSESSMENT (HEALTH CARE); PATHOLOGY, CLINICAL; PROFESSIONAL COMPETENCE; PROGNOSIS; SPECIMEN HANDLING;

EID: 84932635393     PISSN: 10526773     EISSN: 17456614     Source Type: Book Series    
DOI: 10.1093/jncimonographs/lgv016     Document Type: Article

References (20)

1. Provenzano E, Vallier AL, Champ R, et al. A central review of histopathology reports after breast cancer neoadjuvant chemotherapy in the neo-tango trial. Br J Cancer. 2013;108(4):866-872.
2. Rastogi P, Anderson SJ, Bear HD, et al. Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J Clin Oncol. 2008;26(5):778-785.
3. Berruti A, Generali D, Kaufmann M, et al. International expert consensus on primary systemic therapy in the management of early breast cancer: highlights of the Fourth Symposium on Primary Systemic Therapy in the Management of Operable Breast Cancer, Cremona, Italy (2010). J Natl Cancer Inst Monogr. 2011;2011(43):147-151.
4. Marchiò C, Sapino A. The pathologic complete response open question in primary therapy. J Natl Cancer Inst Monogr. 2011;2011(43):86-90.
5. Bear HD, Anderson S, Smith RE, et al. Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer:National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol. 2006;24(13):2019-2027.
6. Fisher B, Bryant J, Wolmark N, et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol. 1998;16(8):2672-2685.
7. Kaufmann M, Hortobagyi GN, Goldhirsch A, et al. Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update. J Clin Oncol. 2006;24(12):1940-1949.
8. Sataloff DM, Mason BA, Prestipino AJ, Seinige UL, Lieber CP, Baloch Z. Pathologic response to induction chemotherapy in locally advanced carcinoma of the breast: a determinant of outcome. J Am Coll Surg. 1995;180(3):297-306.
9. Symmans WF, Peintinger F, Hatzis C, et al. Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol. 2007;25(28):4414-4422.
10. Bonadonna G, Valagussa P, Brambilla C, et al. Primary chemotherapy in operable breast cancer: eight-year experience at the Milan Cancer Institute. J Clin Oncol. 1998;16(1):93-100.
11. Marinovich ML, Houssami N, Macaskill P, et al. Meta-analysis of magnetic resonance imaging in detecting residual breast cancer after neoadjuvant therapy. J Natl Cancer Inst. 2013;105(5):321-333.
12. Williams M, Eatrides J, Kim J, et al. Comparison of breast magnetic resonance imaging clinical tumor size with pathologic tumor size in patients status post-neoadjuvant chemotherapy. Am J Surg. 2013;206(4):567-573.
13. Grimsby GM, Gray R, Dueck A, et al. Is there concordance of invasive breast cancer pathologic tumor size with magnetic resonance imaging? Am J Surg. 2009;198(4):500-504.
14. Sullivan PS, Apple SK. Should histologic type be taken into account when considering neoadjuvant chemotherapy in breast carcinoma? Breast J. 2009;15(2):146-154.
15. Carey LA, Dees EC, Sawyer L, et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res. 2007;13(8):2329-2334.
16. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A, eds. AJCC Cancer Staging Manual.7th ed. New York, NY: Springer; 2010.
17. Tot T. Cost-benefit analysis of using large-format histology sections in routine diagnostic breast care. Breast. 2010;19(4):284-288.
18. Tot T, Gere M. Radiological-pathological correlation in diagnosing breast carcinoma: the role of pathology in the multimodality era. Pathol Oncol Res. 2008;14(2):173-178.
19. Castellano I, Macrì L, Deambrogio C, et al. Reliability of whole sentinel lymph node analysis by one-step nucleic acid amplification for intraoperative diagnosis of breast cancer metastases. Ann Surg. 2012;255(2):334-342.
20. Loya A, Guray M, Hennessy BT, et al. Prognostic significance of occult axillary lymph node metastases after chemotherapy-induced pathologic complete response of cytologically proven axillary lymph node metastases from breast cancer. Cancer. 2009;115(8):1605-1612.